Stock Track | Intellia Therapeutics Soars on Strong Q3 Results and Cash Position

Stock Track11-07 23:00

Intellia Therapeutics Inc. (NASDAQ: NTLA), a leading genome editing company, saw its stock price soar by 5.29% on Wednesday, November 7, 2024, following the release of its third-quarter 2024 financial results and an update on its cash position.

The company reported a narrower-than-expected loss for the third quarter, with a GAAP loss per share of $1.34, beating the analyst consensus estimate of $1.40. This positive earnings surprise was seen as a positive sign by investors, reflecting Intellia's progress in its drug development efforts and effective cost management.

Additionally, Intellia announced that it ended the third quarter of 2024 with approximately $944.7 million in cash, cash equivalents, and marketable securities. This strong cash position is expected to fund the company's operations into late 2026, providing Intellia with ample financial resources to advance its pipeline of genome editing therapies and support its growth initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166561660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166561660","market":"hk","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars on Strong Q3 Results and Cash Position","media":"Stock Track","content":"<p>Intellia Therapeutics Inc. (NASDAQ: NTLA), a leading genome editing company, saw its stock price soar by 5.29% on Wednesday, November 7, 2024, following the release of its third-quarter 2024 financial results and an update on its cash position.</p>\n\n<p>The company reported a narrower-than-expected loss for the third quarter, with a GAAP loss per share of $1.34, beating the analyst consensus estimate of $1.40. This positive earnings surprise was seen as a positive sign by investors, reflecting Intellia's progress in its drug development efforts and effective cost management.</p>\n\n<p>Additionally, Intellia announced that it ended the third quarter of 2024 with approximately $944.7 million in cash, cash equivalents, and marketable securities. This strong cash position is expected to fund the company's operations into late 2026, providing Intellia with ample financial resources to advance its pipeline of genome editing therapies and support its growth initiatives.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars on Strong Q3 Results and Cash Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars on Strong Q3 Results and Cash Position\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 23:00 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics Inc. (NASDAQ: NTLA), a leading genome editing company, saw its stock price soar by 5.29% on Wednesday, November 7, 2024, following the release of its third-quarter 2024 financial...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1166561660","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166561660","pubTimestamp":1730991650,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics Inc. , a leading genome editing company, saw its stock price soar by 5.29% on Wednesday, November 7, 2024, following the release of its third-quarter 2024 financial results and an update on its cash position.The company reported a narrower-than-expected loss for the third quarter, with a GAAP loss per share of $1.34, beating the analyst consensus estimate of $1.40. This positive earnings surprise was seen as a positive sign by investors, reflecting Intellia's progress in it","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"Intellia Therapeutics凭借强劲的第三季度业绩和现金状况飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics Inc. (NASDAQ: NTLA), a leading genome editing company, saw its stock price soar by 5.29% on Wednesday, November 7, 2024, following the release of its third-quarter 2024 financial results and an update on its cash position.\nThe company reported a narrower-than-expected loss for the third quarter, with a GAAP loss per share of $1.34, beating the analyst consensus estimate of $1.40. This positive earnings surprise was seen as a positive sign by investors, reflecting Intellia's progress in its drug development efforts and effective cost management.\nAdditionally, Intellia announced that it ended the third quarter of 2024 with approximately $944.7 million in cash, cash equivalents, and marketable securities. This strong cash position is expected to fund the company's operations into late 2026, providing Intellia with ample financial resources to advance its pipeline of genome editing therapies and support its growth initiatives.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166561660"}